Compositions and methods of use of phorbol esters for the treatment of stroke
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.
1. A method for decreasing the occurrence or recurrence of one or more effects of a stroke in a mammalian subject comprising administering an effective amount of phorbol ester of Formula I, or a pharmaceutically-acceptable salt, isomer, or enantiomer, thereof to said subject
wherein R 1 and R 2 are selected from the group consisting of hydrogen, hydroxyl,
wherein the alkyl group contains 1 to 15 carbon atoms,
wherein the lower alkenyl group contains 1 to 7 carbon atoms,
and R 3 is hydrogen or
wherein the one or more effects of stroke are paralysis, spatial impairment, impaired judgment, left-sided neglect, memory loss, aphasia, coordination and balance problems, nausea, vomiting, cognitive impairment, perception impairment, orientation impairment, homonymous hemianopsia, impaired mobility, or impulsivity.
2. The method of claim 1 , wherein R 1 or R 2 is
the remaining R 1 and R 2 is
and R 3 is hydrogen.
3. The method of claim 1 , wherein the phorbol ester is phorbol 13-butyrate, phorbol 12-decanoate, phorbol 13-decanoate, phorbol 12,13-diacetate, phorbol 13,20-diacetate, phorbol 12,13-dibenzoate, phorbol 12,13-dibutyrate, phorbol 12,13-didecanoate, phorbol 12,13-dihexanoate, phorbol 12,13-dipropionate, phorbol 12-myristate, phorbol 13-myristate, phorbol 12,13,20-triacetate, 12-deoxyphorbol 13-angelate, 12-deoxyphorbol 13-angelate 20-acetate, 12-deoxyphorbol 13-isobutyrate, 12-deoxyphorbol 13-isobutyrate-20-acetate, 12-deoxyphorbol 13-phenylacetate, 12-deoxyphorbol 13-phenylacetate 20-acetate, 12-deoxyphorbol 13-tetradecanoate, phorbol 12-tigliate 13-decanoate, 12-deoxyphorbol 13-acetate, phorbol 12-acetate, or phorbol 13-acetate.
4. The method of claim 1 , wherein the phorbol ester is 12-O-tetradecanoylphorbol-13-acetate.
5. The method of claim 1 , further comprising administering at least one secondary or adjunctive therapeutic agent.
6. The method of claim 5 , wherein the at least one secondary or adjunctive therapeutic agent is administered to said subject in a coordinate administration protocol, simultaneously with, prior to, or after, administration of said phorbol ester to said subject.
7. The method of claim 5 , wherein the at least one secondary or adjunctive therapeutic agent is tissue plasminogen activator, an anticoagulant, a statin, fibrate, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitor, beta-blocker, anti-platelet agent, calcium channel blocker, or diuretic.
8. The method of claim 1 , further comprising surgical intervention in combination with phorbol ester of Formula I.
9. The method of claim 8 , wherein the surgical intervention is a carotid endarterectomy, angioplasty, stent placement, craniotomy, insertion of a pacemaker, implantation of a defibrillator, replacement of valves, coronary artery bypass, heart transplantation, endovascular coil emobilization, or patent foramen ovale closure.
10. A method for decreasing the occurrence or recurrence of one or more symptoms of a stroke comprising administering an effective amount of phorbol ester of Formula I, or a pharmaceutically-acceptable salt, isomer, or enantiomer, thereof to a mammalian subject
wherein R 1 and R 2 are selected from the group consisting of hydrogen, hydroxyl,
wherein the alkyl group contains 1 to 15 carbon atoms,
wherein the lower alkenyl group contains 1 to 7 carbon atoms,
and R 3 is hydrogen or
wherein the one or more symptoms comprise sudden numbness, weakness, sudden confusion, trouble speaking or understanding speech, trouble seeing in one or both eyes, trouble walking, dizziness, loss of balance or coordination, impaired mobility, or sudden headache.
11. The method of claim 10 , wherein R 1 or R 2 is
the remaining R 1 or R 2 is
and R 3 is hydrogen.
12. The method of claim 10 , wherein the phorbol ester is phorbol 13-butyrate, phorbol 12-decanoate, phorbol 13-decanoate, phorbol 12,13-diacetate, phorbol 13,20-diacetate, phorbol 12,13-dibenzoate, phorbol 12,13-dibutyrate, phorbol 12,13-didecanoate, phorbol 12,13-dihexanoate, phorbol 12,13-dipropionate, phorbol 12-myristate, phorbol 13-myristate, phorbol 12,13,20-triacetate, 12-deoxyphorbol 13-angelate, 12-deoxyphorbol 13-angelate 20-acetate, 12-deoxyphorbol 13-isobutyrate, 12-deoxyphorbol 13-isobutyrate-20-acetate, 12-deoxyphorbol 13-phenylacetate, 12-deoxyphorbol 13-phenylacetate 20-acetate, 12-deoxyphorbol 13-tetradecanoate, phorbol 12-tigliate 13-decanoate, 12-deoxyphorbol 13-acetate, phorbol 12-acetate, or phorbol 13-acetate.
13. The method of claim 10 , wherein the phorbol ester is 12-O-tetradecanoylphorbol-13-acetate.
14. The method of claim 10 , further comprising administering at least one secondary or adjunctive therapeutic agent.
15. The method of claim 14 , wherein the at least one secondary or adjunctive therapeutic agent is administered simultaneously with, prior to, or after, administration of said phorbol ester of Formula I.
16. The method of claim 14 , wherein the at least one secondary or adjunctive therapeutic agent is an anticoagulant, a statin, fibrate, angiotensin II receptor blockers, anti-platelet agent, angiotensin-converting enzyme inhibitor, beta-blocker, calcium channel blocker, or diuretic.
17. The method of claim 10 , further comprising surgical intervention in combination with phorbol ester of Formula I.
18. The method of claim 17 , wherein the surgical intervention is a carotid endarterectomy, angioplasty, stent placement, craniotomy, insertion of a pacemaker, implantation of a defibrillator, replacement of valves, coronary artery bypass, heart transplantation, endovascular coil emobilization, or patent foramen ovale closure.
19. A method for treating the sequelae of a stroke in a mammalian subject comprising administering an effective amount of phorbol ester of Formula I, or a pharmaceutically-acceptable salt, isomer, or enantiomer, thereof to said subject
wherein R 1 and R 2 are selected from the group consisting of hydrogen, hydroxyl,
wherein the alkyl group contains 1 to 15 carbon atoms,
wherein the lower alkenyl group contains 1 to 7 carbon atoms,
and R 3 is hydrogen or
20. The method of claim 19 , wherein R 1 or R 2 is
the remaining R 1 or R 2 is
and R 3 is hydrogen.
21. The method of claim 19 , wherein the phorbol ester is phorbol 13-butyrate, phorbol 12-decanoate, phorbol 13-decanoate, phorbol 12,13-diacetate, phorbol 13,20-diacetate, phorbol 12,13-dibenzoate, phorbol 12,13-dibutyrate, phorbol 12,13-didecanoate, phorbol 12,13-dihexanoate, phorbol 12,13-dipropionate, phorbol 12-myristate, phorbol 13-myristate, phorbol 12,13,20-triacetate, 12-deoxyphorbol 13-angelate, 12-deoxyphorbol 13-angelate 20-acetate, 12-deoxyphorbol 13-isobutyrate, 12-deoxyphorbol 13-isobutyrate-20-acetate, 12-deoxyphorbol 13-phenylacetate, 12-deoxyphorbol 13-phenylacetate 20-acetate, 12-deoxyphorbol 13-tetradecanoate, phorbol 12-tigliate 13-decanoate, 12-deoxyphorbol 13-acetate, phorbol 12-acetate, or phorbol 13-acetate.
22. The method of claim 19 , wherein the phorbol ester is 12-O-tetradecanoylphorbol-13-acetate.
23. The method of claim 19 , further comprising administering at least one secondary or adjunctive therapeutic agent.
24. The method of claim 23 , wherein the at least one secondary or adjunctive therapeutic agent is administered to said subject in a coordinate administration protocol, simultaneously with, prior to, or after, administration of said phorbol ester to said subject.
25. The method of claim 23 , wherein the at least one secondary or adjunctive therapeutic agent is tissue plasminogen activator, an anticoagulant, a statin, fibrate, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitor, beta-blocker, anti-platelet agent, calcium channel blocker, or diuretic.
26. The method of claim 19 , further comprising surgical intervention in combination with phorbol ester of Formula I.
27. The method of claim 26 , wherein the surgical intervention is a carotid endarterectomy, angioplasty, stent placement, craniotomy, insertion of a pacemaker, implantation of a defibrillator, replacement of valves, coronary artery bypass, heart transplantation, endovascular coil emobilization, or patent foramen ovale closure.
28. The method of claim 1 , 10 , or 19 , wherein the effective amount of phorbol ester of Formula I is from about 10 to about 1500 μg.
29. The method of claim 28 , wherein the phorbol ester of Formula I is administered per day.